Clene (FRA:84C0) Short Ratio

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:84C0 Clene Inc FRA:84C0
30 GF Score
Price €4.28
GF Value €0.75
Valuation Significantly Overvalued
! 9 Warning Signs
View Full Analysis

What is Clene Short Ratio?

Short Ratio is a metric signaling prevailing investors' sentiment with a company. It represents the number of days it takes short sellers on average to repurchase all the shares short.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

FRA:84C0
30GF Score
Clene Inc FRA:84C0
Short Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Clene (FRA:84C0) Overvalued in 2026?

Based on GuruFocus' analysis, Clene stock appears to be overvalued. The current stock price of €4.28 is trading 470.7% above its estimated GF Value™ of €0.75. GuruFocus considers Clene to be Significantly Overvalued.

Key valuation signals for FRA:84C0:

  • Short Ratio:
  • GF Value™: €0.75 vs. price of €4.28 (470.7% above fair value)
  • GF Score™: 30/100 with 9 warning signs

No single metric tells the full story. See the FRA:84C0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Clene Business Description

Other Exchanges CLNN:USA
Address 6550 South Millrock Drive, Suite G50, Salt Lake City, UT, USA, 84121
Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases. It developed an electro-crystal-chemistry drug development platform that enables the production of concentrated, stable, clean-surfaced nanocrystal suspensions. It operates in one segment the development and commercialization of dietary supplements (Supplements). Products includes CNM-Au8, CNM-ZnA, CNM-AgZn17, rMetx, KHC46.
30GF Score

Get the complete analysis for FRA:84C0

Short Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€4.28
Price
€0.75
GF Value